Actively Recruiting
Evaluating Extended Dosing of Belantamab Mafodotin with Standard Treatments for Relapsed or Refractory Multiple Myeloma
Led by GlaxoSmithKline · Updated on 2026-08-25
200
Participants Needed
59
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for adults with multiple myeloma, a type of blood cancer that has returned or is not responding to current therapies. This Phase 2 study focuses on the drug belantamab mafodotin given less frequently alongside standard cancer medicines to see if it can effectively control the disease while reducing side effects, especially those affecting the eyes. The study also monitors overall treatment response and safety. Participants receive belantamab mafodotin combined with one of three standard regimens pomalidomide plus dexamethasone, bortezomib plus dexamethasone, or carfilzomib plus dexamethasone. The drug dosing is extended to potentially reduce side effects. The study is open-label and non-randomized, with each participant assigned to one of these three treatment combinations. During the study, participants undergo regular assessments including eye exams, tests to measure cancer response, and monitoring for side effects. The main outcome measured is the overall response rate up to about 52 months. Secondary measures include complete response rate, minimal residual disease negativity, duration of response, and detailed safety monitoring including eye-related symptoms. The study lasts until August 2030, with ongoing safety and effectiveness evaluations throughout.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here